Evidence map›Paper›PMID 42660995›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Deep learning augmented pathological grading and intraductal carcinoma of the prostate signatures improve recurrence prediction after intensity-modulated radiation therapy.

Mami Takadate, Rihito Aizawa, Yasushi Numata, Atsushi Marugame, Jyunya Iwazaki, Masao Ueki, Takayuki Takahashi, Kaori Ono, Kotaro Tsutsumi, Hayato Takeda and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Mami TakadateMathematical Intelligence for Medicine, Graduate School of Medicine, Tohoku University, Miyagi, 980-8575, Japan.
Rihito AizawaDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
Yasushi NumataBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan.
Atsushi MarugameBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan.
Jyunya IwazakiDepartment of Artificial Intelligence and Medical Science, Graduate School of Medicine, Tohoku University, Miyagi, 980-8575, Japan.
Masao UekiBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan.
Takayuki TakahashiMathematical Intelligence for Medicine, Graduate School of Medicine, Tohoku University, Miyagi, 980-8575, Japan.
Kaori OnoMathematical Intelligence for Medicine, Graduate School of Medicine, Tohoku University, Miyagi, 980-8575, Japan.
Kotaro TsutsumiBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan.
Hayato TakedaBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan.
Jun AkatsukaBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan.
Yuki EndoDepartment of Urology, Nippon Medical School, Tokyo, 113-8603, Japan.
Yuka ToyamaDepartment of Urology, Nippon Medical School, Tokyo, 113-8603, Japan.
Ryuji OhashiDepartment of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo, 113-8603, Japan.
Akira ShimizuBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan.
Go KimuraBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan.
Hironori HagaDepartment of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
Takashi KobayashiDepartment of Urology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
Yukihiro KondoBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan.
Takashi MizowakiDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
Yoichiro YamamotoMathematical Intelligence for Medicine, Graduate School of Medicine, Tohoku University, Miyagi, 980-8575, Japan. yoichiro.yamamoto@riken.jp.
Toyonori TsuzukiBiomedical Spatial Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, 103-0027, Japan. tsuzuki@aichi-med-u.ac.jp.ORCID http://orcid.org/0000-0002-4855-4366

Funding

japan society for the promotion of science KAKENHI 24K10131Japan Society for the Promotion of Science KAKENHI 21K06933Moonshot Research and Development Program JPMJMS2022-9RIKEN TRIP initiative AGIS
6 · The paper itself

Abstract

Locally advanced prostate cancer (PCa) is associated with a high recurrence rate even after curative treatment. We aimed to develop a precise risk model by integrating the status of intraductal carcinoma of the prostate (IDC-P) and the International Society of Urological Pathology Grade Group (ISUP GG) with deep learning (DL)-based grading to predict clinical recurrence after intensity-modulated radiation therapy (IMRT). Furthermore, we identified key pathological features associated with IDC-P. We retrospectively analyzed 165 patients treated with high-dose IMRT for high- and very high-risk PCa at two institutions. Pathological features were extracted from hematoxylin and eosin-stained specimens from 100 cases using a DL-based model, from which an expert pathologist selected 10 cancer-related features. The area under the curve (AUC) values derived from split-sample validation for predicting clinical recurrence using ISUP GG and IDC-P status were 0.732 and 0.735, respectively, and 0.789 for their combination. Integrating 10 key features further improved the AUC to 0.850, with robust performance in external validation (AUC = 0.833). Kaplan-Meier analysis showed a significant difference (p < 0.05) in clinical recurrence between high- and low-risk prediction groups. Additionally, we identified four DL-derived pathological features that are significantly associated with IDC-P (p < 0.05). Incorporation of ISUP GG, IDC-P status, and DL-derived pathological features improves the prediction of clinical recurrence after high-dose IMRT in high- and very high-risk PCa. Our findings underscore the clinical significance of IDC-P and support optimized treatment strategies.

Indexed as

Clinical recurrenceDeep learningHigh-risk prostate cancerIntraductal carcinoma of the prostateRadiation therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.